An uphill path to commercialization of silver nanoparticle antimicrobials: from bench to market

Nanomedicine (Lond). 2025 Sep;20(18):2305-2308. doi: 10.1080/17435889.2025.2518914. Epub 2025 Jun 19.

Authors

Sanil Nadar¹, Anan Safwat¹, Nan Qin², Daniel M Czyż^{1

3}

Affiliations

¹ Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, USA.
² Research and Development Department, Natural Immunogenics Corporation, Sarasota, FL, USA.
³ Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.

PMID: 40536419
PMCID: PMC12413069 (available on 2026-06-19)
DOI: 10.1080/17435889.2025.2518914

No abstract available

Keywords: AgNPs; Silver nanoparticles; antimicrobial resistance; antimicrobials; commercialization; manufacturing; therapeutics.

Publication types

Editorial